ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1067

Efficacy of Double-Dose Influenza Vaccine with a Booster Compared with Standard Dose in Hemodialysis Patients: Randomized Controlled Trial

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Ritveeradej, Ekapol, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Boonnak, Kobporn, Mahidol University Faculty of Tropical Medicine, Bangkok, Bangkok, Thailand
  • Yoowannakul, Suree, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand

Patients on hemodialysis may be at higher risk of illness and death from infected of influenza virus. The efficacy of dose of influenza vaccine across dialysis patients is uncharacterized. We assessed the efficacy of double-dose and booster influenza vaccine versus standard-dose in hemodialysis patients.


A prospective, open-label, randomized study with 100 hemodialysis patients were enrolled. Double-dose and booster group(n=50) received two doses of IM inactivated seasonal quadrivalent influenza vaccine and one dose at the next 2 weeks while standard-dose group(n=50) received one dose of vaccine. Demographics and co-morbidity were collected at baseline. HAI titers were assessed prior to vaccination and at 14, 28 days post-vaccination.


Hemodialysis patients had age of 61 years approximately and had similar baseline laboratory and co-morbidity. Double-dose with booster group had higher rate of seroprotection(100% vs 86%, p=0.006) and seroconversion(84% vs 60%, p=0.008) measured by using HAI against H3N2 were different significantly. Moreover, Double-dose with booster group had higher rate of sustained antibody level at 4 weeks after first vaccination measured by using HAI against H1N1(88% vs 52%, p=0.006) and H3N2(84% vs 72%, p=0.003) were significant differences. However, no differences in HAI against B strains were seen. At 4 weeks after first vaccination, HAI against H1N1, H3N2, B/Colorado and B/Yamagata are similar in both groups.


The double-dose with booster influenza vaccine can provide higher seroprotection and seroconversion rates of HAI against in H3N2 but no different in other strains compared to standard-dose. This study is needed to explore the effect of double-dose with booster vaccine against all causes mortality or influenza related outcomes for adults undergoing hemodialysis compared to the standard-dose.


  • Private Foundation Support